Cytiva ÄKTA oligosynt™ Oligonucleotide Synthesizer

Overview

The Cytiva ÄKTA oligosynt™ Oligonucleotide Synthesizer is a compact, fully automated benchtop platform engineered for robust, scalable solid-phase oligonucleotide synthesis using the industry-standard phosphoramidite chemistry. Unlike traditional column-based or electrochemical-only systems, the ÄKTA oligosynt™ implements a flow-through synthesis architecture—where reagents are delivered under precise pressure control across functionalized solid supports housed in disposable synthesis columns. This design minimizes dead volume (< 50 µL), ensures consistent reagent delivery kinetics, and enables reproducible coupling efficiency across scales from research-grade (10–200 µmol) to early process development (up to 12 mmol). The system operates under ambient temperature conditions with integrated real-time monitoring of critical process parameters—including column backpressure, solvent flow integrity (bubble detection), ambient and column temperature, UV absorbance (for dimethoxytrityl [DMT] cleavage monitoring), and conductivity (for wash step verification). Its modular fluidic architecture conforms to ISO 8573-1 Class 3 compressed air purity requirements and supports integration with external environmental sensors or process analyzers via analog/digital I/O ports.

Key Features

• Flow-through synthesis technology with <50 µL system dead volume for high reagent utilization and reduced waste generation
• Scalable synthesis capacity spanning 10 µmol (analytical scale) to 12 mmol (pilot-scale process development)
• Integrated multi-parameter sensor suite: pressure transducers (±0.1 bar resolution), optical bubble detectors, PT100 temperature probes (±0.2 °C), UV-Vis flow cell (260 nm DMT monitoring), and conductivity cells for endpoint validation
• Touchscreen-driven user interface with drag-and-drop method editor, real-time graphical workflow visualization, and context-aware error diagnostics
• Modular hardware design compliant with IEC 61000-6-2/6-4 electromagnetic compatibility standards; CE-marked and UL-listed for laboratory use
• Onboard method storage (≥100 protocols) with timestamped versioning and audit-trail-enabled editing history

Sample Compatibility & Compliance

The ÄKTA oligosynt™ accommodates standard 1–4 mL fritted synthesis columns packed with controlled-pore glass (CPG), polystyrene, or oxalyl-modified supports—compatible with DNA, RNA, LNA, 2′-O-methyl, phosphorothioate, and dye-labeled phosphoramidites. All fluidic pathways contact only PEEK, PTFE, or 316 stainless steel wetted materials, ensuring compatibility with acetonitrile, dichloroacetic acid, iodine/water/pyridine, and oxidizing agents such as tert-butyl hydroperoxide. The system meets ISO 13485 design control requirements for medical device-related oligonucleotide development and supports ALCOA+ data integrity principles. Full electronic records—including raw sensor logs, method execution metadata, and event timestamps—are exportable in CSV and PDF/A-2 format for regulatory submissions under FDA 21 CFR Part 11 and EU Annex 11.

Software & Data Management

UNICORN™ 7.2 software (included) provides GxP-ready method development, execution, and reporting capabilities. It features role-based access control (RBAC), electronic signatures, and automated audit trail generation compliant with 21 CFR Part 11. All synthesis runs generate structured metadata including column ID, lot traceability, reagent batch numbers, environmental readings, and real-time coupling efficiency estimates derived from DMT cation UV peak integration. Data exports support direct import into LIMS platforms via OPC UA or RESTful API endpoints. Historical method performance analytics—including average step yield, cycle time deviation, and reagent consumption variance—are available through built-in trend analysis dashboards.

Applications

• Rapid prototyping of antisense oligonucleotides (ASOs), siRNA duplexes, and CRISPR guide RNAs for target validation studies
• Process parameter screening (e.g., coupling time, activator concentration, deblocking acid strength) during early-stage工艺 development
• Generation of clinical trial material intermediates under GLP-compliant workflows
• Method transfer to production-scale synthesizers (e.g., ÄKTA oligopilot™) via standardized UNICORN method templates
• Quality-by-Design (QbD) studies supporting ICH Q5A(R2) and Q5B guidelines for nucleic acid therapeutics

FAQ

What synthesis chemistry does the ÄKTA oligosynt™ support?
It uses standard phosphoramidite solid-phase synthesis with optional electrochemical oxidation for sulfurization steps—fully compatible with commercial phosphoramidite monomers and solid supports.
Can the system be integrated into an automated lab environment?
Yes—it supports Ethernet/IP and Modbus TCP protocols for bidirectional communication with robotic liquid handlers, environmental chambers, and central LIMS infrastructure.
Is method transfer to larger-scale synthesizers supported?
UNICORN methods are natively portable to ÄKTA oligopilot™ and ÄKTA pure™ platforms, preserving gradient profiles, valve sequencing, and sensor-triggered logic without manual reconfiguration.
Does the system comply with FDA 21 CFR Part 11 requirements?
Yes—UNICORN 7.2 provides full electronic signature capability, audit trail logging, and role-based permissions validated per IQ/OQ protocols supplied by Cytiva.
What maintenance is required for long-term operational reliability?
Preventive maintenance includes quarterly calibration of pressure and temperature sensors, annual replacement of fluidic seals, and biannual verification of UV lamp intensity and conductivity cell accuracy—documented in the included service logbook module.